{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:39:56Z","timestamp":1793813996339,"version":"4.6.1"},"reference-count":17,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0583-3","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T02:05:34Z","timestamp":1556071534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features"],"prefix":"10.1136","volume":"7","author":[{"given":"Jonathan D.","family":"Schoenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Severgnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Manos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond H.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,4,24]]},"reference":[{"key":"583_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/CMAR.S136818","volume":"9","author":"S Chuzi","year":"2017","unstructured":"Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res. 2017;9:207\u201313.","journal-title":"Cancer Manag Res"},{"issue":"12","key":"583_CR2","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced Cancer: a systematic review and meta-analysis. JAMA oncology. 2016;2(12):1607\u201316.","journal-title":"JAMA oncology"},{"issue":"5","key":"583_CR3","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.ijrobp.2006.08.058","volume":"66","author":"PG Tsoutsou","year":"2006","unstructured":"Tsoutsou PG, Koukourakis MI. Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys. 2006;66(5):1281\u201393.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"583_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0360-3016(99)00183-2","volume":"45","author":"MV Graham","year":"1999","unstructured":"Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45(2):323\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"583_CR5","doi-asserted-by":"crossref","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018.","DOI":"10.1056\/NEJMoa1809697"},{"issue":"2","key":"583_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijrobp.2017.02.003","volume":"98","author":"A Bang","year":"2017","unstructured":"Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int J Radiat Oncol Biol Phys. 2017;98(2):344\u201351.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"583_CR7","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","volume":"36","author":"JJ Luke","year":"2018","unstructured":"Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, et al. Safety and clinical activity of Pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36(16):1611\u20138.","journal-title":"J Clin Oncol"},{"issue":"10","key":"583_CR8","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41416-018-0281-9","volume":"119","author":"A Maity","year":"2018","unstructured":"Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, et al. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br J Cancer. 2018;119(10):1200\u20137.","journal-title":"Br J Cancer"},{"issue":"6","key":"583_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1470-2045(12)70138-9","volume":"13","author":"BH Burmeister","year":"2012","unstructured":"Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. The Lancet Oncology. 2012;13(6):589\u201397.","journal-title":"The Lancet Oncology"},{"issue":"19","key":"583_CR10","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med"},{"issue":"24","key":"583_CR11","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","volume":"22","author":"M Nishino","year":"2016","unstructured":"Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, et al. PD-1 inhibitor-related pneumonitis in advanced Cancer patients: radiographic patterns and clinical course. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22(24):6051\u201360.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"3","key":"583_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1056\/NEJMc1505197","volume":"373","author":"M Nishino","year":"2015","unstructured":"Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-related pneumonitis during Cancer immunotherapy. N Engl J Med. 2015;373(3):288\u201390.","journal-title":"N Engl J Med"},{"issue":"4","key":"583_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1158\/2326-6066.CIR-15-0267","volume":"4","author":"M Nishino","year":"2016","unstructured":"Nishino M, Chambers ES, Chong CR, Ramaiya NH, Gray SW, Marcoux JP, et al. Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung Cancer. Cancer immunology research. 2016;4(4):289\u201393.","journal-title":"Cancer immunology research"},{"key":"583_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cellsig.2018.11.004","volume":"54","author":"K Rajarathnam","year":"2018","unstructured":"Rajarathnam K, Schnoor M, Richardson RM, Rajagopal S. How do chemokines navigate neutrophils to the target site: dissecting the structural mechanisms and signaling pathways. Cell Signal. 2018;54:69\u201380.","journal-title":"Cell Signal"},{"issue":"1","key":"583_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40425-018-0408-9","volume":"6","author":"P Friedlander","year":"2018","unstructured":"Friedlander P, Wood K, Wassmann K, Christenfeld AM, Bhardwaj N, Oh WK. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. J Immunother Cancer. 2018;6(1):90.","journal-title":"J Immunother Cancer"},{"key":"583_CR16","doi-asserted-by":"crossref","unstructured":"Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018.","DOI":"10.1158\/1078-0432.CCR-18-2795"},{"issue":"6","key":"583_CR17","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/annonc\/mdx115","volume":"28","author":"R Shibaki","year":"2017","unstructured":"Shibaki R, Akamatsu H, Fujimoto M, Koh Y, Yamamoto N. Nivolumab induced radiation recall pneumonitis after two years of radiotherapy. Annals of oncology : official journal of the European Society for Medical Oncology \/ ESMO. 2017;28(6):1404\u20135.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology \/ ESMO"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0583-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0583-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0583-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T18:18:08Z","timestamp":1663352288000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0583-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,24]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["583"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0583-3","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,24]]},"assertion":[{"value":"6 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Data and samples were collected on a DF-HCC institutionally review board approved protocol (05\u2013042).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Schoenfeld reports grants, personal fees and non-financial support from Bristol-Myers Squibb, grants from Merck, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Debiopharm, personal fees from Nanobiotix, personal fees from Tilos Therapeutics, grants from Regeneron, all outside the submitted work.Dr. Nishino reports she is a Consultant to Toshiba Medical Systems, WorldCare Clinical, Daiichi Sankyo; Research grant from Merck Investigator Studies Program, Canon Medical Systems, AstraZeneca; and Honorarium from Bayer, Roche.Dr. Mak reports AstraZeneca (Scientific Advisory Board), NewRT (honorarium).Dr. Hodi reports grants, personal fees and consulting from Bristol-Myers Squibb, personal fees from Merck, personal fees from EMD Serono, personal fees from Novartis, personal fees from Celldex, personal fees from Amgen, personal fees from Genentech\/Roche, personal fees from Incyte, personal fees from Apricity, personal fees from Bayer, personal fees from Aduro, personal fees from Partners Therapeutics, personal fees from Sanofi, personal fees from Pfizer, personal fees from Pionyr, is an upaid advisor for 7 Hills Pharma, personal fees from Verastem, other from Torque, personal fees from Compass Therapeutics, personal fees from Takeda, outside the submitted work; In addition, Dr. Hodi has a patent Methods for Treating MICA-Related Disorders (#20100111973) with royalties paid, a patent Tumor antigens and uses thereof (#7250291) issued, a patent Angiopoiten-2 Biomarkers Predictive of Anti-immune checkpoint response (#20170248603) pending, a patent Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms (#20160340407) pending, a patent Therapeutic peptides (#20160046716) pending, a patent Therapeutic Peptides (#20140004112) pending, a patent Therapeutic Peptides (#20170022275) pending, a patent Therapeutic Peptides (#20170008962) pending, a patent THERAPEUTIC PEPTIDES Patent number: 9402905 issued, and a patent METHODS OF USING PEMBROLIZUMAB AND TREBANANIB pending.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"112"}}